Last reviewed · How we verify

DTPw-HBV/Hib-MenAC conjugate vaccine — Competitive Intelligence Brief

DTPw-HBV/Hib-MenAC conjugate vaccine (DTPw-HBV/Hib-MenAC conjugate vaccine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Combination conjugate vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

DTPw-HBV/Hib-MenAC conjugate vaccine (DTPw-HBV/Hib-MenAC conjugate vaccine) — GlaxoSmithKline. This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C through conjugate technology.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DTPw-HBV/Hib-MenAC conjugate vaccine TARGET DTPw-HBV/Hib-MenAC conjugate vaccine GlaxoSmithKline phase 3 Combination conjugate vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination conjugate vaccine class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTPw-HBV/Hib-MenAC conjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtpw-hbv-hib-menac-conjugate-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: